Close
Biotechgate
| |

Home Page

News in the Life Sciences Industry

Results 441 - 460 out of 500 displayed.
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22 23  24  25 »
Reset 

Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Third Consecutive Year

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019
Related companies:  Flexion Therapeutics Inc.

Generex Declares 1:1 Stock Dividend

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019
Related companies:  Generex Biotechnology Corp. | Genovior Biotech Corporation

Philips extends advanced automation capabilities on its EPIQ CVx cardiology ultrasound platform, making accurate exams faster and easier to conduct

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019

CMS Alum and Industry Veteran Meg Koepke Joins NovuHealth as Vice President of Strategy

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019
Related companies:  NovuHealth

TG Therapeutics Announces Data Presentations at the 15th International Conference on Malignant Lymphoma

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019
Related companies:  TG Therapeutics, Inc.

Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019
Related companies:  Sienna Biopharmaceuticals, Inc.

UPDATE - Sharps Compliance Releases New Solution Offering for the Safe and Compliant Cleanup of Spilled Hazardous Drugs

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019

Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019
Related companies:  Ritter Pharmaceuticals, Inc.

Kane Biotech and Nestlé Reach Settlement

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019
Related companies:  Kane Biotech Inc.

SEC Investigation of Misonix, Inc. Ends With No Action

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019
Related companies:  Misonix, Inc.

BeiGene Announces Phase 1b Clinical Results of Zanubrutinib in Combination with GAZYVA® (Obinutuzumab) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Follicular Lymphoma at the 15th International Conference on Malignant L

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019
Related companies:  BeiGene, Ltd.

Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019
Related companies:  OSE Immunotherapeutics

Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019

Valneva Announces Mutual Agreement with GSK to End Strategic Alliance Agreement; Regains Control of R&D

Read more ››
By: Nasdaq / GlobenewsWire - 20 Jun 2019

CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting

GENOA, Italy, June 20, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that it will support the presentation... Read more ››

By: PR Newswire Association LLC. - 20 Jun 2019

Definiens & Targos Innovation: AI-powered multiplex IHC biomarker analytic solutions for precision medicine

Collaboration to bolster end-to-end services from assay development to confident informed clinical decision making

Read more ››
By: PR Newswire Association LLC. - 20 Jun 2019
Related companies:  Definiens AG

Cyxone Initiates First-in-human Trial With T20K for the Treatment of MS

STOCKHOLM, June 20, 2019 /PRNewswire/ -- Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company starts its first-in-human, phase I, clinical trial with drug candidate T20K for the treatment of multiple sclerosis (MS) immediately following the authorities'... Read more ››

By: PR Newswire Association LLC. - 20 Jun 2019
Related companies:  Cyxone AB

Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly

LUND, Sweden, June 20, 2019 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX), a commercial stage biopharmaceutical company specializing in long-acting medicines for severe and chronic disorders, announced today the acceptance by the US Food and Drug Administration (FDA) of an Investigational New Drug... Read more ››

By: PR Newswire Association LLC. - 20 Jun 2019
Related companies:  CAMURUS AB

RS Components Completes Nationwide 'Tour de Branch' Bike Ride to Help Fight the Injustice of Childhood Cancer

LONDON, June 20, 2019 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 20 Jun 2019

SPIE To Acquire Photonex, UK's Top Photonics Exhibition

BELLINGHAM, Wash. and CARDIFF, Wales, June 20, 2019 /PRNewswire/ -- SPIE, the international society for optics and photonics, has... Read more ››

By: PR Newswire Association LLC. - 20 Jun 2019
«  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22 23  24  25 »
to the top ↑